Climb Bio
CLYM
47 hedge funds and large institutions have $355M invested in Climb Bio in 2024 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 10 increasing their positions, 4 reducing their positions, and 5 closing their positions.
668% more capital invested
Capital invested by funds: $46.2M → $355M (+$309M)
520% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 5
150% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 4
124% more funds holding
Funds holding: 21 → 47 (+26)
106.63% more ownership
Funds ownership: 61.14% → 167.76% (+107%)
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$122M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$26M |
| 3 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$21.7M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$21.7M |
| 5 |
BC
Boxer Capital
San Diego,
California
|
+$17.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$6.01M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$770K |
| 3 |
AI
Atom Investors
Austin,
Texas
|
-$214K |
| 4 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$80.7K |
| 5 |
Millennium Management
New York
|
-$58K |
CLYM Hedge Fund Activity: Q2 2024 in Review
47 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Climb Bio (CLYM) for Q2 2024, worth a combined $355M — up 668% from $46.2M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new CLYM positions and 5 closed out — a net gain of 26 holders — while 10 added to existing stakes and 4 trimmed.
The largest buyer was RA Capital Management, adding an estimated $122M. The largest seller was BML Capital Management, exiting entirely with an estimated $6.01M sold.
- 47 institutional investors held Climb Bio (CLYM) as of Q2 2024, up from 21 in Q1 2024.
- Funds reported $355M of Climb Bio stock for Q2 2024, up 668% quarter-over-quarter.
- 31 funds opened new Climb Bio positions in Q2 2024 and 5 closed out, a net change of +26 holders.
- The largest Climb Bio buyer in Q2 2024 was RA Capital Management, an estimated $122M added.
- The largest Climb Bio seller in Q2 2024 was BML Capital Management, an estimated $6.01M sold.
Based on aggregated 13F filings for Q2 2024.